



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

30 Nov 2015

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

Important notices

- Clarifying NIH Priorities for Health Economics Research ([NOT-OD-16-025](#))
- Revised SF424 (R&R) Application Guides and Supplemental Instructions Available for Application Due Dates On and Between January 25, 2016 and May 24, 2016 ([NOT-OD-16-029](#))
- Publication of the Revised NIH Grants Policy Statement (Rev. 11/2015) for FY 2016 ([NOT-OD-16-030](#))
- Notice of an Update to the Key Dates in RFA-AI-15-055 "B Cell Immunology Program for HIV-1 Vaccine Development (BCIP) (R01)" ([NOT-AI-16-010](#))
- Notice of Extension of the Expiration Date for PAR-15-166 "NIAMS Clinical Trial Planning Cooperative Agreement (U34)" ([NOT-AR-16-009](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Behavioral & Integrative Treatment Development Program (R01) ([NOT-DA-16-004](#))

1. Pediatric Diagnostic Biomarkers for Active Pulmonary TB Disease

Letter of Intent due date: N/A

Hyperlink: [\(RFA-AI-15-057\)](#) Type: R01

Application Due Date: March 11, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support projects to identify and/or validate biomarkers or biomarker combinations leading to improved diagnosis of active pulmonary tuberculosis (TB) in children, including HIV infected children.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. BRAIN Initiative: Non-Invasive Neuromodulation - New Tools and Techniques for Spatiotemporal Precision

Letter of Intent due date: January 18, 2016

Hyperlink: [\(RFA-MH-16-810\)](#) Type: R01

Application Due Date: February 18, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications in two related but distinct areas. The first area is in the development and testing of novel tools and methods of neuromodulation that go beyond the existing variations on magnetic or electrical stimulation, and that represent more than an incremental advance over existing electromagnetic approaches. The second distinct area that this FOA seeks to encourage is the optimization of existing electrical and magnetic stimulation methods.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is four years.

3. BRAIN Initiative: Non-Invasive Neuromodulation - Mechanisms and Dose/Response Relationships for Targeted CNS

Letter of Intent due date: January 18, 2016

Hyperlink: Type: R01

Application Due Date: February 18, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The focus of this Funding Opportunity Announcement (FOA) is to better understand how existing non-invasive neuromodulation devices affect brain circuitry. This information should shed light on dose/response relationships that could be used for neuroscience applications and clinical interventions.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is four years.

4. Revision Applications for Validation of Mobile/Wireless Health Tools for Measurement and Intervention

Letter of Intent due date: 30 days before each receipt date **Hyperlink:** [\(PA-16-043\)](#) **Type:** RO1

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) invites revision applications from investigators and institutions/organizations with active NIH-supported research project awards to support an expansion of the scope of approved and funded projects to incorporate recent advances in mobile/wireless tools to validate these tools for measurement and intervention delivery. Revision applications for projects that do not currently employ mobile/wireless tools are welcome provided that the applicant team has the requisite scientific and technical expertise to employ and validate these tools. Research efforts have failed to keep pace with the rapid and exponential advancements in mobile/wireless health technologies in recent years. By supporting revisions to existing RO1 projects, this FOA encourages the rapid validation of mobile/wireless tools for health measurement and intervention delivery. The focus of this FOA is on recently developed mobile/wireless health tools including sensor technologies and smartphone applications. While some additional programming may be required to customize or integrate the technology into the existing project, this FOA is not intended to support new technology development, but instead to clinically validate recently developed but not yet validated tools.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants may request support for up to 2 years, not to exceed the remaining number of years on the parent grant. If a no-cost extension is needed on the parent grant to incorporate the project period of the competitive revision, the no cost extension must be in place before the revision application is submitted.

5. Drug Discovery For Nervous System Disorders

Letter of Intent due date: N/A **Hyperlink:** [\(PAR-16-041\)](#) **Type:** RO1
[\(PAR-16-042\)](#) R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders.

Budget: **RO1-** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. **R21 -** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in a single year. The maximum project period is 2 years.

6. Image-guided Drug Delivery

Letter of Intent due date: N/A **Hyperlink:** [\(PAR-16-044\)](#) **Type:** RO1

Application Due Date: June 21, 2016; November 22, 2016; June 21, 2017; November 22, 2017; June 21, 2018; November 22, 2018. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period is 5 years.

7. Planning Grant for Emerging Epidemic Virus Research Training for West African Countries with Widespread Transmission of Ebola-Guinea, Liberia, and Sierra Leone

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** **Type:** D71

Application Due Date: February 24, 2016 by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement invites applications from U.S. or African research institutions to plan research training and capacity building programs focused on emerging viral epidemics in collaboration with institutions in Guinea, Liberia, and/or Sierra Leone. The application should propose a collaborative planning process to develop training approaches that will create sustainable research capacity for the early identification, transmission prediction, testing of public health responses, and assessing and addressing long term health sequelae related to emerging viral diseases that have the potential for regional and global pandemics.

Budget: Application budgets are limited to a maximum of \$50,000 total costs.

Grantees are expected to be familiar with and comply with applicable cost policies and the NRSA Guidelines (NIH Grants Policy Statement - Institutional Research Training Grants). Funds may be used only for those expenses that are directly related to and necessary for the research training planning process and must be expended in conformance with OMB Cost Principles, the NIH Grants Policy Statement, and the regulations, policies, guidelines, and conditions set forth in this document. The maximum project period is one year.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

DP3 – Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award: To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

P20 – Research Program Projects and Centers -Exploratory Grant: To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete [Glossary and acronym list of NIH Terms](#)



Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: **Dr Christa Coetsee** • Tel: 9838 • Email: cdevries@sun.ac.za